Search research articles
Contact Us
Filters
Showing results (51-60 of 113) with videos related to
Page
of 12
Sort By:
JAMA Neurology
|
May 30, 2018
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
Virginia L Stauffer, David W Dodick, Qi Zhang, et al.
Postgraduate Medicine
|
March 18, 2021
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine
David B Clemow, Helen M Hochstetler, Yan Dong, et al.
Neurology and Therapy
|
February 11, 2026
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial
Patricia Pozo-Rosich, Cristina Tassorelli, Line Pickering Boserup, et al.
Therapeutic Advances in Neurological Disorders
|
June 10, 2025
Measuring incremental burdens associated with increasing preventive-treatment failures among adults with migraine: a retrospective, cross-sectional study
Jessica Ailani, Nemin Chen, Avani Patel, et al.
JAMA
|
November 20, 2019
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
Richard B Lipton, David W Dodick, Jessica Ailani, et al.
The New England Journal of Medicine
|
December 5, 2019
Ubrogepant for the Treatment of Migraine
David W Dodick, Richard B Lipton, Jessica Ailani, et al.
The Journal of Headache and Pain
|
April 12, 2024
Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR)
Nina Sharp, Mark J Burish, Kathleen B Digre, et al.
Current Medical Research and Opinion
|
September 28, 2024
Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study
Jessica Ailani, Motomori Lewis, Feng Dai, et al.
Headache
|
September 1, 2023
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis
E Anne MacGregor, Susan Hutchinson, Hongxin Lai, et al.
Cephalalgia : an International Journal of Headache
|
June 12, 2016
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Richard B Lipton, Noah L Rosen, Jessica Ailani, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 113) with videos related to
Sort By:
Page
of 12
JAMA Neurology
|
May 30, 2018
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
Virginia L Stauffer, David W Dodick, Qi Zhang, et al.
Postgraduate Medicine
|
March 18, 2021
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine
David B Clemow, Helen M Hochstetler, Yan Dong, et al.
Neurology and Therapy
|
February 11, 2026
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial
Patricia Pozo-Rosich, Cristina Tassorelli, Line Pickering Boserup, et al.
Therapeutic Advances in Neurological Disorders
|
June 10, 2025
Measuring incremental burdens associated with increasing preventive-treatment failures among adults with migraine: a retrospective, cross-sectional study
Jessica Ailani, Nemin Chen, Avani Patel, et al.
JAMA
|
November 20, 2019
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
Richard B Lipton, David W Dodick, Jessica Ailani, et al.
The New England Journal of Medicine
|
December 5, 2019
Ubrogepant for the Treatment of Migraine
David W Dodick, Richard B Lipton, Jessica Ailani, et al.
The Journal of Headache and Pain
|
April 12, 2024
Photophobia is associated with lower sleep quality in individuals with migraine: results from the American Registry for Migraine Research (ARMR)
Nina Sharp, Mark J Burish, Kathleen B Digre, et al.
Current Medical Research and Opinion
|
September 28, 2024
Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study
Jessica Ailani, Motomori Lewis, Feng Dai, et al.
Headache
|
September 1, 2023
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis
E Anne MacGregor, Susan Hutchinson, Hongxin Lai, et al.
Cephalalgia : an International Journal of Headache
|
June 12, 2016
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Richard B Lipton, Noah L Rosen, Jessica Ailani, et al.
Page
of 12